ArticleClinical epigenetics2026
Effectiveness analysis and clinical application potential exploration of combined detection of PAX1/JAM3 gene methylation in early diagnosis of cervical precancerous lesions.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the application of gene methylation detection in cervical cancer screening.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe early and accurate diagnosis of cervical precancerous lesions is essential for mitigating the risk of cervical cancer. Given the limitations of traditional screening methods, such as inadequate sensitivity and low specificity, this study aims to assess the diagnostic performance of combined PAX1/JAM3 gene methylation testing for cervical intraepithelial neoplasia (CIN) and to explore its potential in triage management. Methylation testing serves as a tool for investigating the epigenetic alterations associated with diseases like cancer, thereby providing molecular biological evidence for diagnosis and prognosis.
methodsThis study included 431 cervical exfoliated cell samples, which consisted of CIN1, CIN2/3, cervical cancer (CC), and control groups. The methylation levels of the PAX1/JAM3 genes were assessed using quantitative methylation-specific PCR. The diagnostic efficacy of these genes for high-grade lesions (CIN2+) was analyzed through receiver operating characteristic (ROC) curve analysis and was compared with HPV testing and cytological examination. Additionally, the diagnostic performance of PAX1/SOX1 methylation was preliminarily evaluated in a sub-cohort of 100 cases. Further evaluation was conducted on the triage referral rate and the impact of clinical intervention using this biomarker in HPV-positive patients.
resultsThe area under the curve (AUC) for the PAX1/JAM3 methylation test in diagnosing CIN2+ was 0.89 (95% CI: 0.85-0.92), with a sensitivity of 83.1% and a specificity of 88.8%. In the sub-cohort, the PAX1/SOX1 combination also demonstrated high diagnostic potential for CIN3+ (AUC = 0.91), serving as a validation of methylation testing efficacy. In non-HPV16/18 positive patients, the sensitivity and specificity of methylation testing for CIN2+ were superior to those of cytology. Among patients undergoing colposcopy, 265 cases had results of ≤ASCUS, of which 51 were methylation positive, resulting in a colposcopy referral rate of 19.3%.
conclusionPAX1/JAM3 gene methylation testing demonstrates strong diagnostic efficacy for cervical precancerous lesions and holds significant potential in triage diagnosis. The PAX1/SOX1 panel also shows promise as a complementary biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.